Reservations to receive the Novavax vaccine in Korea were officially opened on February 21st via the coronavirus disease 2019 (COVID-19) vaccination reservation system website (ncvr2.kdca.go.kr). The vaccine, also referred to as “Nuvaxovid” and “NVX-CoV2373,” was developed by Novavax, Inc., an American biotechnology company. The Novavax vaccine is the first protein-based COVID-19 vaccine; it was developed using the same procedure as the hepatitis B and pertussis vaccines. Clinical trials in the United States and the United Kingdom revealed that those injected with the second dose demonstrated a 100% vaccine efficacy against severe cases of COVID-19 and a 90% efficacy against infection of the disease. Cases of serious side effects were also recorded to be under 1%. Although the actual implementation of the Novavax vaccine was on February 14th, it had only been available to the unvaccinated over the age of 18, serious inpatient cases, and nursing facility residents. Those who wished to recieve the vaccine had to reserve a no-show vaccine through Kakaotalk or Naver. However, starting from the 21st, reservations were also opened to the public. Administration dates can be selected two weeks after the day of reservation. Moreover, cross vaccination for those who received other types of COVID-19 vaccinations but suffered for various medical reasons is also available at the discretion of the doctor. On March 3rd, the Korea Disease Control and Prevention Agency reported that 57% of the 9,700 citizens who were vaccinated between February 24th and March 2nd received the Novavax vaccine, showing an effective increase in vaccination rates.